XIV Congreso Internacional de Investigación y Práctica Profesional en Psicología. XXIX Jornadas de Investigación. XVIII Encuentro de Investigadores en Psicología del MERCOSUR. IV Encuentro de Investigación de Terapia Ocupacional. IV Encuentro de Musicoterapia. Facultad de Psicología - Universidad de Buenos Aires, Buenos Aires, 2022.

El sistema renina angiotensina como objetivo terapéutico para reducir síntomas de Ansiedad en enfermedad de Parkinson.

Bordet, Sofía y Perez Lloret, Santiago.

EL SISTEMA RENINA ANGIOTENSINA COMO OBJETIVO TERAPÉUTICO PARA REDUCIR SÍNTOMAS DE ANSIEDAD EN ENFERMEDAD DE PARKINSON

Bordet, Sofía; Perez Lloret, Santiago
Pontificia Universidad Católica Argentina. Buenos Aires, Argentina.

RESUMEN

La enfermedad de Parkinson es un trastorno neurodegenerativo que afecta el sistema nervioso. Entre los síntomas no motores, la ansiedad afecta significativamente la calidad de vida. Diversos estudios sugieren que el Sistema Renina-Angiotensina cerebral (SRA) participaría en el desarrollo de la ansiedad, tanto en esta como en otras enfermedades. El objetivo del presente trabajo es analizar los efectos de fármacos bloqueantes de los receptores AT1 (BRA) y los inhibidores de la enzima convertidora de angiotensina (IECA), ya que estos fármacos modulan el SRA. Muestra: 423 pacientes con Parkinson de reciente comienzo, seguidos por 5 años. La variable de interés primario fue el puntaje en la escala de valoración de ansiedad State-Trait Anxiety Inventory (STAI). Resultados: Los pacientes que recibían BRA mostraron puntajes de STAI más bajos en comparación con los que no los recibían (p=0.021). De igual manera los pacientes expuestos a BRAs mostraron puntajes más bajos de STAI durante los tres primeros años del seguimiento. No se observó ningún efecto de los IECA. Estos resultados sugieren que la desregulación del SRA contribuye al desarrollo de la ansiedad en el Parkinson y que los BRAs podrían utilizarse para su tratamiento. Se necesitan conducir ensayos clínicos aleatorizados, doble ciego confirmatorios.

Palabras clave
Enfermedad de Parkinson - Ansiedad - Renina Angiotensina - Tratamiento

ABSTRACT

THE RENIN ANGIOTENSIN SYSTEM AS A THERAPEUTIC TARGET TO REDUCE ANXIETY SYMPTOMS IN PARKINSON'S DISEASE

Parkinson's disease is a neurodegenerative disorder that affects the nervous system. Among non-motor symptoms, anxiety significantly affects quality of life. Various studies suggest that the cerebral Renin-Angiotensin System (RAS) would participate in the development of anxiety, both in this and in other diseases. The aim of this study is to analyze the effects of AT1 receptor blocking drugs (ARBs) and angiotensin converting enzyme inhibitors (ACEIs), since these drugs modulate the RAS. Sample: 423 patients with recent-onset Parkinson's, followed up for 5 years. The primary variable of interest was the State-Trait Anxiety Inventory (STAI) anxiety assessment scale score. Results: Patients receiving ARBs showed lower STAI scores compared to those not receiving ARBs (p=0.021). Similarly, patients exposed to ARBs showed lower STAI scores during the first three years of follow-up. No effect of ACE inhibitors was observed. These results suggest that RAS dysregulation contributes to the development of anxiety in Parkinson's and that ARBs could be used to treat it. Confirmatory, double-blind, randomized clinical trials need to be conducted.

Keywords
Parkinson's disease - Anxiety - Renin Angiotensin - Treatment

BIBLIOGRAFÍA

Aarsland, D., & Kramberger, M. (2015) Neuropsychiatric Symptoms in Parkinson's Disease. *Journal Of Parkinson's Disease, 5*(3), 659-667. https://doi.org/10.3233/jpd-150604

Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., & Rascol, O. et al. (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *The Lancet Neurology, 9*(6), 573-580. https://doi.org/10.1016/s1474-4422(10)70106-x

Benicky, J., Sánchez-Lemus, E., Honda, M., Pang, T., Orecna, M., & Wang, J. et al. (2010) Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation. *Neuropsychopharmacology, 36*(4), 857-870. https://doi.org/10.1038/npp.2010.225

Broen, M., Narayen, N., Kuijf, M., Dissanayaka, N., & Leentjens, A. (2016) Prevalence of anxiety in Parkinson's disease: A systematic review and meta-analysis. *Movement Disorders, 31*(8), 1125-1133. https://doi.org/10.1002/mds.26643

Brownstein, D., Salagre, E., Köhler, C., Stubbs, B., Vian, J., & Pereira, C. et al. (2017) Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials. *Australian &Amp; New Zealand Journal Of Psychiatry, 52*(1), 24-38. https://doi.org/10.1177/0004867417721654

Chrissobolis, S., Luu, A., Waldschmidt, R., Yoakum, M., & D'Souza, M. (2020) Targeting the renin angiotensin system for the treatment of anxiety and depression. *Pharmacology Biochemistry And Behavior, 199*, 173063. https://doi.org/10.1016/j.pbb.2020.173063

Ge, J., & Barnes, N. (1996) Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. *European Journal Of Pharmacology, 297*(3), 299-306. https://doi.org/10.1016/0014-2999(95)00762-8

Genaro, K., Fabris, D., Fachim, H., & Prado, W. (2017) Angiotensin AT1 receptors modulate the anxiogenic effects of angiotensin (5-8) injected into the rat ventrolateral periaqueductal gray. *Peptides, 96*, 8-14. https://doi.org/10.1016/j.peptides.2017.08.005

Hommel, A., Meinders, M., Lorenzl, S., Dodel, R., Coelho, M., & Ferreira, J. et al. (2020) The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. *Movement Disorders Clinical Practice, 7*(5), 531-542. https://doi.org/10.1002/mdc3.12968

Kalia, L., & Lang, A. (2015) Parkinson's disease. *The Lancet, 386*(9996), 896-912. http://dx.doi.org/10.1016/S0140-6736(14)61393-3

Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., & Simuni, T. et al. (2011) The Parkinson Progression Marker Initiative (PPMI). *Progress In Neurobiology, 95*(4), 629-635. https://doi.org/10.1016/j.pneurobio.2011.09.005

Martínez-Martín, P., & Payo, B. (1998) Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. *Journal Of Neurology, 245*(S1), S34-S38. https://doi.org/10.1007/pl00007737

Otero-Losada, M., Nobile, M., & Milei, J. (2017) The Angiotensin Affair: How Great Minds Thinking Alike Came to a Historical Agreement. Renin-Angiotensin System - Past, Present And Future, 3-12. https://doi.org/10.5772/67136

Pechlivanova, D., Krumova, E., Kostadinova, N., Mitreva-Staleva, J., Grozdanov, P., & Stoynev, A. (2020) Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats. *Metabolic Brain Disease, 35*(3), 527-538. https://doi.org/10.1007/s11011-020-00534-1

Perez-Lloret, S., Otero-Losada, M., Toblli, J., & Capani, F. (2017) Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. *Expert Opinion On Investigational Drugs*, *26*(10), 1163-1173. https://doi.org/10.1080/13543784.2017.1371133

Poewe, W., Gauthier, S., Aarsland, D., Leverenz, J., Barone, P., Weintraub, D., Tolosa, E., Dubois, B. (2008) Diagnosis and management of Parkinson's disease dementia. *International Journal Of Clinical Practice, 62*(10), 1581-1587. https://doi.org/10.1111/j.1742-1241.2008.01869.x

Poewe, W., Gauthier, S., Aarsland, D., Leverenz, J., Barone, P., Weintraub, D., Tolosa, E., Dubois, B. (2008) Diagnosis and management of Parkinson's disease dementia. *International Journal Of Clinical Practice, 62*(10), 1581-1587. https://doi.org/10.1111/j.1742-1241.2008.01869.x

Prediger, R., Matheus, F., Schwarzbold, M., Lima, M., & Vital, M. (2012) Anxiety in Parkinson's disease: A critical review of experimental and clinical studies. *Neuropharmacology, 62*(1), 115-124. https://doi.org/10.1016/j.neuropharm.2011.08.039

Reijnders, J., Ehrt, U., Weber, W., Aarsland, D., & Leentjens, A. (2007) A systematic review of prevalence studies of depression in Parkinson's disease. *Movement Disorders, 23*(2), 183-189. https://doi.org/10.1002/mds.21803

Saavedra, J. (2021) Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore. *Physiology, 36*(3), 160-173. https://doi.org/10.1152/physiol.00036.2020

Salmani, H., Hosseini, M., Baghcheghi, Y., Moradi-Marjaneh, R., & Mokhtari-Zaer, A. (2020) Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-? activation. *Cytokine, 125*, 154860. https://doi.org/10.1016/j.cyto.2019.154860

Spielberger, C. (2010) State-Trait Anxiety Inventory. The Corsini Encyclopedia Of Psychology. https://doi.org/10.1002/9780470479216.corpsy0943

Spielberger, C.D., Gorsuch, R., y Lushene, R. (1970) Manual for the StateTrait Anxiety Inventory. Palo Alto, California: Consulting Psychologist Press.

Tashev, R., & Ivanova, M. (2018) Involvement of hippocampal angiotensin 1 receptors in anxiety-like behaviour of olfactory bulbectomized rats. *Pharmacological Reports, 70*(5), 847-852. https://doi.org/10.1016/j.pharep.2018.03.001

Tchekalarova, J., Ivanova, N., Pechlivanova, D., Atanasova, D., Lazarov, N., & Kortenska, L. et al. (2014) Antiepileptogenic and neuroprotective effects of losartan in kainate model of temporal lobe epilepsy. *Pharmacology Biochemistry And Behavior, 127*, 27-36. https://doi.org/10.1016/j.pbb.2014.10.005

Tysnes, O., & Storstein, A. (2017) Epidemiology of Parkinson's disease. *Journal Of Neural Transmission, 124*(8), 901-905. https://doi.org/10.1007/s00702-017-1686-y

Vian, J., Pereira, C., Chavarria, V., Köhler, C., Stubbs, B., & Quevedo, J. et al. (2017) The renin-angiotensin system: a possible new target for depression. *BMC Medicine, 15*(1). https://doi.org/10.1186/s12916-017-0916-3

Weintraub, D., & Mamikonyan, E. (2019) The Neuropsychiatry of Parkinson Disease: A Perfect Storm. *The American Journal Of Geriatric Psychiatry, 27*(9), 998-1018. https://doi.org/10.1016/j.jagp.2019.03.002

Weintraub, D., & Mamikonyan, E. (2019) The Neuropsychiatry of Parkinson Disease: A Perfect Storm. *The American Journal Of Geriatric Psychiatry, 27*(9), 998-1018. https://doi.org/10.1016/j.jagp.2019.03.002

WHOCC - Guidelines. Whocc.no. (2021) https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/.